The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As per Abingdons RNS today it looks like technical transfer of the AVCT test has not started to their manufacturing partners. A process that takes 2 months at a push.
With regards to the original post this is why most scientists in the space prefer either the statistical measures of Positive and negative percent agreement or the 95% confidence intervals around stated values for sensitivity and specificity. Both of those measures take into account sample size and so are very detrimentally affected by a small study number. In fact if i remember correctly the TPP for LFTs actually states a minimum 95%CI lower boundary target to be met rather than up front values.
Sorry to the BRH holders i dont get why AVCT is always ramped here its a different product with a different intended use. I just prefer to lay out the facts when i see them.
For the record i hope all mentioned companies do well. GLA
It was 56 samples, its now undergoing clinical validation with a much larger sample size, news due in the coming days.
I would like to watch the interview you have been mentioning, can someone post a link, cheers
Just report him everything he comes. Alternatively go to Avatca and promote BRH that should stop him. Send them Carls interview.
BRH is just beginning its major upward trend can see big gains to be made from the current price just from the back of a successful Covid test. Then we have been told that the testing also works for Sepsis what next certain types of cancer if so then the value of our product will get truly get mind boggling. My prediction and the reason I am invested in hear is for when one of the Big Pharmaceutical companies buy us out simples. As has been stated before if successful then we are talking multiple pounds not pence folks.!!!!
Mumbo sadly you are correct, it seems a lot of rival company investors are purposely derailing our share and promoting theirs. Why I post every now and again is to stop these derampers misleading people.
Neutron doner, goto my thread on avacta about E484K variant and you will see the true faces of some of these characters.
I am sorry , you cant even make a single counter. Everyone gold bows out. We have CE approval anticipated in a month and a half.
Hmmm, 2 minutes vs 20 minutes.
We could have CE approval now but we decided to make a product which has a great sensitivity and specificity as well as fast diagnostic time.
So we maybe a bit late to market but we will deliver a better product.
The tortoise won the race after all.
And they are worth near 600 million. Think I'll pass on that please. BRH 1200 million will do nicely. Currently 20 odd million.
Goldtrig you still here trying to be a saviour to the masses. Haha how about putting some time into investing rather than shorting. Tomorrow will most likely be another up day and the shorters will hurt some more. If your not one of them shorting then what are you actually doing here nobody needs your advice or has ever asked for it..???
Excellent. Should post On Avatca get the big buyers here.
They tested 26 negative samples for specificity. Got to say the smaller the sample size the more skewed your results are and the more meaningless.
Its not clear if they tested only 30 positive samples to determine the sensitivity, but it looks like they have . That is also too small to draw a reliable conclusion.
Hence why avacta are doing more clinical validation of there test which is still not on the market.
Paraytec have a bigger sample size , the software of the tests are being adjusted to pick up lower amounts of covid virion, we are at same point as avacta. Although we have the potential to push our test to market now, instead we are optimizing it to be more efficient.